HBsAg LOSS IN CHRONIC HEPATITIS B PATIENTS WITH SUBCUTANEOUS PD-L1 ANTIBODY ASC22 (ENVAFOLIMAB) PLUS NUCLEOS(T)IDE ANALOGS TREATMENT: INTERIM RESULTS FROM A PHASE IIb CLINICAL TRIAL
机构：[1]Peking Univ First Hosp, Beijing, Peoples R China[2]Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China[3]Xiamen Hosp Tradit Chinese Med, Xiamen, Peoples R China[4]Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai, Peoples R China[5]Shenyang Sixth Peoples Hosp, Shenyang, Peoples R China[6]Capital Med Univ, Youan Hosp, Beijing, Peoples R China[7]Peking Univ, Shenzhen Hosp, Beijing, Peoples R China[8]Second Hosp Nanjing, Nanjing, Peoples R China[9]Sichuan Univ, West China Hosp, Chengdu, Peoples R China四川大学华西医院[10]Anhui Med Univ, Affiliated Hosp 2, Hefei, Peoples R China[11]Shanghai Tongren Hosp, Shanghai, Peoples R China[12]Cent South Univ, Xiangya Hosp, Beijing, Peoples R China[13]Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Peoples R China[14]First Hosp Jilin Univ, Changchun, Peoples R China[15]Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China[16]Ascletis Biosci Co Ltd, Hangzhou, Peoples R China
第一作者机构：[1]Peking Univ First Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Wang Guiqiang,Cui Yimin,Xie Yao,et al.HBsAg LOSS IN CHRONIC HEPATITIS B PATIENTS WITH SUBCUTANEOUS PD-L1 ANTIBODY ASC22 (ENVAFOLIMAB) PLUS NUCLEOS(T)IDE ANALOGS TREATMENT: INTERIM RESULTS FROM A PHASE IIb CLINICAL TRIAL[J].HEPATOLOGY.2021,74(6):1392A-1392A.doi:10.1002/hep.32218.
APA：
Wang, Guiqiang,Cui, Yimin,Xie, Yao,Mao, Qianguo,Xie, Qing...&Wu, Jinzi J..(2021).HBsAg LOSS IN CHRONIC HEPATITIS B PATIENTS WITH SUBCUTANEOUS PD-L1 ANTIBODY ASC22 (ENVAFOLIMAB) PLUS NUCLEOS(T)IDE ANALOGS TREATMENT: INTERIM RESULTS FROM A PHASE IIb CLINICAL TRIAL.HEPATOLOGY,74,(6)
MLA：
Wang, Guiqiang,et al."HBsAg LOSS IN CHRONIC HEPATITIS B PATIENTS WITH SUBCUTANEOUS PD-L1 ANTIBODY ASC22 (ENVAFOLIMAB) PLUS NUCLEOS(T)IDE ANALOGS TREATMENT: INTERIM RESULTS FROM A PHASE IIb CLINICAL TRIAL".HEPATOLOGY 74..6(2021):1392A-1392A
医学